What impacted Eli Lilly's research and development costs in 2024?


Aime
Eli Lilly's research and development (R&D) costs in 2024 were impacted by several key factors:
- Strategic Investments: The company significantly increased its R&D expenses due to investments in both ongoing and new late-phase opportunities1. This indicates a strategic move to bolster its drug pipeline and prepare for future growth.
- Acquisitions: The recognition of acquired in-process research and development (IPR&D) charges, primarily from the Morphic Therapeutics acquisition, contributed to the rise in R&D expenses23. These charges reflect the costs associated with acquiring intellectual property and technologies that enhance Lilly's pipeline.
- Portfolio Expansion: The expansion of manufacturing facilities and the announcement of a $4.5 billion research facility, the Lilly Medicine Foundry, suggest a long-term commitment to R&D4. While these investments may not immediately impact the financials, they will influence costs in the coming years as these facilities are brought online.
- Regulatory Approvals and Clinical Trials: The company's achievements in regulatory approvals, such as the FDA approval of Kisunla in the US, Japan, and Great Britain, and the approval of Eliquis in the US, indicate ongoing R&D efforts and the associated costs of clinical trials and regulatory submissions5.
In summary, Eli Lilly's R&D costs in 2024 were influenced by strategic investments, acquisitions, facility expansions, and the ongoing development of new treatments. These activities are critical for maintaining a competitive edge in the pharmaceutical sector and are reflected in the company's financial statements.
Source:
p
1.
Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance
more
less
Continue this conversation 

Explore
Screener
Analysis
Learn
Wiki